Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to first determine the maximum tolerated dose of capecitabine
given alone or in combination with valproic acid during preoperative short-course
radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition
of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal
radical surgery might increase the pathologic complete tumor regression rate in patients with
low-moderate risk rectal cancer.